News | June 10, 2025
Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies
Globally, BRUKINSA is approved in more than 70 countries
Globally, BRUKINSA is approved in more than 70 countries
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
The portfolio includes branded injectable cephalosporines for infectious diseases
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Subscribe To Our Newsletter & Stay Updated
